PROMO!
First order? Get 10% OFF with this code: 1storder
Humanin is a mitochondrial-derived peptide (MDP) and is encoded within the mitochondrial 16S rRNA region, investigated in preclinical and cellular research examining mitochondrial stress responses, apoptosis-associated signalling, cellular metabolism and neurobiological pathways.
Humanin is a peptide derived from the mitochondria (MDP) which was first identified as a result of studies concerning mitochondrial-associated genetic sequences and the cellular response to stress. The fact that it was discovered helped to establish the idea that small open reading frames linked to mitochondrial RNA are capable of encoding biologically active peptides, thus extending the scientific knowledge of mitochondrial gene expression and signaling.
Humanin is considered one of the earliest characterized members of the broader mitochondrial-derived peptide family, a group of small peptides associated with mitochondrial-to-cell communication. It has subsequently become an important experimental molecule for studying how peptide signals originating from, or associated with, mitochondrial genetic regions participate in cellular regulatory processes.
The peptide is studied primarily as a defined molecular research tool in biochemical, cellular, and preclinical systems. Humanin research has also provided a foundation for investigating other mitochondrial-derived peptides and mitochondrial small open reading frames, contributing to the developing field of mitochondrial peptide biology.
There is now a large body of research dealing with native Humanin as well as with Humanin analogs that have been deliberately designed. Since these are different experimental molecules, they should be treated as separate cases when interpreting or comparing research results.
Humanin is a linear 24-amino-acid peptide containing a leucine-rich hydrophobic region and a basic C-terminal region containing lysine and arginine residues. Its primary sequence includes one cysteine and one methionine, accounting for the sulfur content of the molecule. With only one cysteine residue, monomeric Humanin cannot form an intramolecular cysteine–cysteine disulfide bond.
Structural studies show that Humanin is conformationally flexible and that its secondary structure is affected by the experimental environment surrounding it; in some less-polar or membrane-associated conditions an increased α-helical character has been observed.
Humanin should be distinguished from modified analogues such as S14G-Humanin (HNG) and from alternative salt forms, as these represent chemically distinct research materials.
Humanin appears to act through multiple intracellular and extracellular signalling mechanisms, rather than through a single established molecular target. Current mechanistic models are based largely on biochemical, cellular and preclinical experiments, and the relative contribution of each pathway appears to depend on the experimental system.
Interaction with Apoptosis-Associated Proteins
One of the most extensively investigated intracellular mechanisms involves Humanin's interaction with proteins of the BCL-2-associated apoptotic signalling network. Biochemical studies have demonstrated direct interactions with BAX, as well as the BH3-associated proteins Bid/tBid and BimEL. In experimental systems, Humanin–BAX interaction has been associated with altered BAX activation and reduced translocation of BAX to mitochondrial membranes, linking the peptide to research on mitochondrial outer-membrane permeabilisation and programmed cell-death signalling.
CNTFR/WSX-1/gp130 Signalling
Humanin has also been investigated as an extracellular signalling peptide. Experimental evidence indicates interaction with a receptor complex involving CNTFRα, WSX-1 and gp130. Receptor-binding and loss-of-function experiments have connected this complex with activation of STAT3, while gp130-associated signalling may additionally involve JAK and MAPK/ERK pathways. The precise organisation and dynamics of the Humanin receptor complex remain subjects of investigation.
Formyl Peptide Receptor Research
There is another area of research which has looked at formyl peptide receptors, especially FPRL1/FPR2, as possible mediators of Humanin-associated signalling. Experimental studies have associated this receptor system with various intracellular events such as calcium mobilisation and ERK1/2 signalling. Yet the dependence on the receptor has varied among different cellular models, suggesting that FPR-associated signalling may account for only one part of Humanin's molecular activity.
Mitochondrial and Cellular Stress Signalling
Together, these findings position Humanin within research on mitochondrial-to-cell communication, stress-response signalling and regulation of apoptosis-associated pathways. Importantly, its mechanism remains multifaceted and model-dependent. Intracellular protein interactions and extracellular receptor-mediated signalling should therefore be considered complementary areas of investigation rather than a single fully established mechanism.
These observations derive primarily from biochemical, in-vitro and preclinical research and should not be interpreted as evidence of clinical efficacy or therapeutic suitability.
This summary reflects findings reported in published preclinical and in vitro research. The original studies supporting this information are listed in the references.
Humanin is extensively studied as part of the wider area of mitochondrial-derived peptide signalling. Experimental studies make use of Humanin in order to find out how mitochondria convey information about cellular stress beyond the usual metabolic pathways and how mitochondrial-derived signals affect subsequent cellular responses.
Cellular models have examined Humanin under experimentally induced oxidative stress, including changes in reactive oxygen species, mitochondrial function and stress-responsive signalling. For example, research in human retinal pigment epithelial cells has investigated Humanin alongside measurements of mitochondrial respiration, ROS formation and mitochondrial DNA-related parameters.
Humanin is used in mechanistic studies of mitochondria-associated apoptosis. Particular attention has been given to its interactions with proteins including BAX, Bid and IGFBP-3, as well as downstream processes associated with mitochondrial membrane signalling and caspase activation. These studies provide experimental systems for examining how peptide–protein interactions influence programmed cell-death pathways.
Another research area concerns Humanin's extracellular signalling behaviour. Studies have examined a receptor complex involving CNTFR, WSX-1 and gp130, together with downstream JAK/STAT3 signalling. Formyl peptide receptor-associated pathways and ERK1/2 signalling have also been investigated, allowing comparison between different proposed mechanisms of extracellular Humanin activity.
Humanin provides a research model for studying relationships between peptide signalling and mitochondrial bioenergetics. Experimental endpoints have included mitochondrial respiration, mitochondrial biogenesis-associated markers, membrane function and responses to experimentally induced mitochondrial stress. These effects can vary substantially according to cell type and experimental conditions.
Research has also linked Humanin to the protein-quality-control mechanisms involved in chaperone-mediated autophagy. Experiments have examined its connection with lysosomal processes and the management of oxidised or damaged proteins, thus offering another way of studying Humanin as part of cellular stress-response networks.
Humanin and other similar compounds have been studied in cellular and animal models, the research focusing on metabolic signalling, the body's responses to nutrients and stress resistance. This work aids in the wider investigation into how mitochondrial-derived peptides interact with the cell's energy-detecting and adaptive signalling pathways.
Modified Humanin sequences, including S14G-Humanin (HNG), are used experimentally to investigate how individual amino-acid substitutions affect peptide activity and molecular interactions. Such comparisons are useful for structure–activity relationship studies but findings obtained with an analogue should not automatically be attributed to native Humanin.
Research Note: These areas are based primarily on biochemical, cellular and preclinical studies. Findings should be interpreted within the specific experimental model, peptide form and assay conditions used.
The research material consisting of peptides should be examined for peptide identity and for chromatographic purity by means of complementary analytical methods. RP-HPLC can be used to determine the purity and to separate the main peptide from impurities associated with synthesis or from degradation products, whereas mass spectrometry (MS) can help to establish molecular identity by comparing the observed molecular mass with the expected one.
Because Humanin contains methionine and cysteine, oxidation and related modifications may also be relevant during analytical assessment. Where additional structural information is required, techniques such as NMR or circular dichroism (CD) may be used.
Analytical findings should be reviewed alongside the batch-specific Certificate of Analysis, including the stated peptide form, identity and purity.
Humanin should be stored according to its specific chemical form and batch documentation. As a general laboratory guideline, lyophilized peptide material should be kept sealed at approximately −20°C or below, protected from moisture, light and unnecessary temperature fluctuations.
Before you open the container, place the sealed package into the laboratory temperature environment to reduce the formation of condensation; since humanin contains both methionine and cysteine residues, oxidation and other related modifications must be taken into account when the substance is being stored or analysed.
For prepared laboratory solutions, stability depends on factors including solvent, concentration, pH and temperature. Repeated freeze–thaw cycles should be minimised. The batch-specific Certificate of Analysis, manufacturer stability data and validated laboratory SOPs should always take precedence over general storage recommendations.
Humanin is classified as a mitochondrial-derived peptide because its original coding sequence was identified within a small open reading frame associated with the mitochondrial 16S rRNA (MT-RNR2) region. Its discovery helped establish the broader concept that mitochondrial sequences can encode small signalling peptides in addition to their conventional RNA functions.
Humanin research encompasses several interconnected pathways, including mitochondrial stress signalling, apoptosis-associated mechanisms, JAK/STAT signalling and ERK-associated signalling. These pathways are investigated through biochemical, cellular and preclinical models, and their relative importance appears to depend on experimental conditions.
BAX is an apoptosis-associated protein and one of the best-characterised intracellular binding partners investigated for Humanin. Experimental studies indicate that Humanin can interact with BAX and influence processes including its conformational activation, mitochondrial association and oligomerisation, making this interaction useful for studying mitochondria-associated apoptotic signalling.
Two principal receptor systems have been investigated: formyl peptide receptors (FPRL1/FPR2) and a heterotrimeric receptor complex comprising CNTFRα, WSX-1 and gp130. Experimental research associates these receptor systems with downstream pathways including ERK and JAK/STAT signalling.
As a mitochondrial-derived peptide, Humanin provides an experimental model for examining how mitochondrial-associated signals can influence cellular processes beyond the mitochondrion itself. Research into its intracellular protein interactions and extracellular receptor signalling contributes to the wider study of mitochondrial retrograde and intercellular communication.
S14G-Humanin, commonly abbreviated HNG, is a Humanin analogue in which the serine residue at position 14 is replaced by glycine. It is frequently used in structure–activity research to examine how a single amino-acid substitution changes the molecular behaviour of the Humanin sequence.
No. Modified analogues can have different conformational properties and experimental activities from the native Humanin sequence. Findings obtained with HNG or another Humanin analogue should therefore be identified as analogue-specific unless equivalent effects have been independently demonstrated with native Humanin.
No single mechanism fully accounts for the experimental observations reported for Humanin. Research describes both intracellular protein interactions involving molecules such as BAX, Bid and IGFBP-3 and extracellular receptor-mediated signalling, indicating a multifaceted and model-dependent mechanism.
The identity of a peptide can be established by comparing the molecular mass that has been observed in an experiment with the mass that is expected on the basis of the specified Humanin sequence. If chromatographic separation is used and, where appropriate, MS/MS fragmentation data are also taken into account, this offers additional evidence for telling the desired peptide apart from related or modified molecular species.
Published information describes Humanin generally, but it does not establish the identity or purity of an individual supplied batch. Batch-specific analytical documentation, including chromatographic purity, molecular identity and chemical form, is therefore important for confirming that research material corresponds to its stated specification.
Humanin is offered for laboratory research and analytical work only. The material is not for human or animal use, including consumption or administration, and is not supplied for clinical, diagnostic, therapeutic or veterinary purposes.
Content relating to Humanin’s molecular pathways and experimental activity is provided as research information only. Findings discussed on this page should be considered in the context of the studies and experimental models from which they were reported, rather than as evidence of therapeutic or clinical effects.
